BridgeBio Soars

US FDA approves BridgeBio's drug for rare heart condition (Nov 22)
(This Nov. 22 story has been corrected to fix the list price of Pfizer's drug to about $268,000, not $225,000, in paragraph 3) (Reuters) - The U.S. Food and Drug Administration has approved BridgeBio's drug for a rare and deadly heart condition,
BridgeBio Soars After Drug Gets Nod in Serious Heart Condition
BridgeBio Pharma Inc. jumped in premarket trading after its drug got US regulators’ nod to treat a deadly form of heart disease, paving the way for head-to-head competition with medications from Pfizer Inc.
FDA approves BridgeBio’s Attruby for ATTR-CM treatment
The US Food and Drug Administration (FDA) has approved BridgeBio Pharma’s Attruby (acoramidis), an oral transthyretin (TTR) stabiliser, to treat adults with transthyretin amyloid cardiomyopathy (ATTR-CM).
BridgeBio’s Attruby wins FDA approval
The US Food and Drug Administration (FDA) on Friday approved Attruby (acoramidis), an orally-administered near-complete (≥90%) stabilizer of Transthyretin (TTR) for the treatment of adults with ATTR-CM to reduce cardiovascular death and cardiovascular-related hospitalization.
FDA approves Palo Alto biotech's heart disease drug
The stock market responded positively to the company's announcement, with its share price leaping more than 28% following the opening bell Monday.
BridgeBio wins FDA approval for heart disease drug
The Food and Drug Administration approved on Friday a new medicine from BridgeBio for patients with a progressive heart disease — the first new treatment for the condition in over five years and the company’s first significant commercial product. The drug, known scientifically as acoramidis, will be sold by BridgeBio under the brand name Attruby.
BridgeBio Pharma Gets FDA Approval for Heart Disease Drug Attruby
The Palo Alto, California-based biopharmaceutical company said the Food and Drug Administration approved Attruby for adults with transthyretin amyloid cardiomyopathy, or ATTR-CM, to reduce cardiovascular death and cardiovascular-related hospitalization.
BridgeBio heart drug approved by FDA, setting up battle with Pfizer
The approval of Attruby for transthyretin amyloidosis with cardiomyopathy begins a battle for control of a lucrative market that investors have been skeptical BridgeBio can win.
BridgeBio's Breakthrough in Rare Heart Condition Treatment
The U.S. FDA has approved Attruby, a new drug by BridgeBio, for treating a rare heart condition, redefining a market led by Pfizer’s Vyndaqel. Meanwhile, Canada has reported its first case of clade I mpox,
BridgeBio Pharma : FDA Approves Heart Disease Drug 'acoramidis'
BridgeBio Pharma Inc. (BBIO) announced that the U.S. Food and Drug Administration approved Attruby or acoramidis, an
devdiscourse2d
Revolutionary Drug Approvals and Global Health Updates
The latest health news highlights BridgeBio's new heart drug approved by the FDA, novel findings in breast cell research, ...
BridgeBio announces FDA approved Attruby for ATTR-CM patients
Pharma announced that the U.S. Food and Drug Administration approved Attruby, an orally-administered near-complete stabilizer ...